MedDataX Logo

Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort

NCT ID: NCT06629090

Last Updated: 2025-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-17

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Brain blood flow will be measured during a simulated postural change test and while breathing increased levels of carbon dioxide using magnetic resonance imaging.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Global cerebral blood flow (CBF) decreases with advancing age; however, some adults have accelerated declines in CBF, placing them at a greater risk of cognitive impairment. However, there is a lack of human studies that investigate the cause or consequence of altered blood flow regulation in the brain. This study will systematically address this gap in knowledge by examining cerebrovascular control in adults during acute physiological challenges (simulated postural change test and breathing increased carbon dioxide) that stimulate a change in CBF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Magnetic Resonance Imaging Cerebrovascular Circulation

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Magnetic Resonance Imaging Brain Blood Flow Lower Body Negative Pressure Carbon Dioxide

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Young Adults

Young Adults between 20-40 years of age.

Group Type EXPERIMENTAL

MRI

Intervention Type DEVICE

Participants will undergo an MRI scan while performing breathing and simulated postural change tasks.

Prazosin

Intervention Type DRUG

A dose of prazosin will be administered based on body weight

Placebo

Intervention Type DRUG

Oral placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI

Participants will undergo an MRI scan while performing breathing and simulated postural change tasks.

Intervention Type DEVICE

Prazosin

A dose of prazosin will be administered based on body weight

Intervention Type DRUG

Placebo

Oral placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Between the ages of 20-40 years
* Have a BMI ≤34.5 kg/m2
* are less than 72 in (182.88 cm) height
* Nonsmoker

Exclusion Criteria

* Diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's disease (AD)
* History or evidence of hepatic disease, hematological disease, or peripheral vascular disease; severe kidney injury requiring hemodialysis
* History of cardiovascular disease including: severe congestive heart failure, coronary artery disease, ischemic heart disease (stents, coronary artery bypass grafts) and tachycardia
* Uncontrolled hypertension
* History of clinically significant ischemic or hemorrhagic stroke, or significant cerebrovascular disease
* Severe untreated obstructive sleep apnea
* History of diabetes with HbA1c greater than 9.5 percent
* Major neurologic disorders other than dementia (e.g., MS, ALS, brain surgery, etc.)
* Current or recent (less than1 year) major psychiatric condition (Axis I) or addictive disorders
* Significant surgical history
* Other significant medical conditions at investigators' discretion
* Contraindications to MRI
* Prescribed medications that interfere with prazosin
* Lactose allergy
* lower body will not fit in lower body negative pressure (LBNP) chamber (regardless of overall height and BMI)
Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Wisconsin, Madison

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jill Barnes, PhD

Role: PRINCIPAL_INVESTIGATOR

UW Madison

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Wisconsin

Madison, Wisconsin, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anna Howery

Role: CONTACT

Phone: 608-262-9572

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Anna J Howery, MS

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A176000

Identifier Type: OTHER

Identifier Source: secondary_id

EDUC/KINESIOLOGY

Identifier Type: OTHER

Identifier Source: secondary_id

Protocol Version 7/29/2025

Identifier Type: OTHER

Identifier Source: secondary_id

2024-0377: Younger Cohort

Identifier Type: -

Identifier Source: org_study_id